Jan J. Melenhorst

1.6k total citations
10 papers, 316 citations indexed

About

Jan J. Melenhorst is a scholar working on Oncology, Pathology and Forensic Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Jan J. Melenhorst has authored 10 papers receiving a total of 316 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 3 papers in Pathology and Forensic Medicine and 3 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Jan J. Melenhorst's work include CAR-T cell therapy research (10 papers), Acute Lymphoblastic Leukemia research (3 papers) and Lymphoma Diagnosis and Treatment (3 papers). Jan J. Melenhorst is often cited by papers focused on CAR-T cell therapy research (10 papers), Acute Lymphoblastic Leukemia research (3 papers) and Lymphoma Diagnosis and Treatment (3 papers). Jan J. Melenhorst collaborates with scholars based in United States and Switzerland. Jan J. Melenhorst's co-authors include Simon F. Lacey, Carl H. June, Bruce L. Levine, David L. Porter, Katherine T. Marcucci, Stephen J. Schuster, Stephan A. Grupp, Gabriela Plesa, Gregory L. Beatty and Pamela A. Shaw and has published in prestigious journals such as Journal of Clinical Oncology and Blood.

In The Last Decade

Jan J. Melenhorst

10 papers receiving 306 citations

Peers

Countries citing papers authored by Jan J. Melenhorst

Since Specialization

Citations

This map shows the geographic impact of Jan J. Melenhorst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan J. Melenhorst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan J. Melenhorst more than expected).

Fields of papers citing papers by Jan J. Melenhorst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan J. Melenhorst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan J. Melenhorst. The network helps show where Jan J. Melenhorst may publish in the future.

Co-authorship network of co-authors of Jan J. Melenhorst

This figure shows the co-authorship network connecting the top 25 collaborators of Jan J. Melenhorst. A scholar is included among the top collaborators of Jan J. Melenhorst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan J. Melenhorst. Jan J. Melenhorst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Effect of chimeric antigen receptor (CAR) T cells on clonal expansion of endogenous non-CAR T cells in patients (pts) with advanced solid cancer. 2017 ·Journal of Clinical Oncology ·(unknown), Gabriela Plesa, Whitney L. Gladney, Irina Kulikovskaya, Bruce L. Levine, Simon F. Lacey, Carl H. June, Jan J. Melenhorst, Gregory L. Beatty	5
2	Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL). 2017 ·Journal of Clinical Oncology ·Mala K. Talekar, Shannon L. Maude, George Hucks, Laura Motley, Colleen Callahan, Claire White, Diane Baniewicz, David M. Barrett, Susan R. Rheingold, Simon F. Lacey, Bruce L. Levine, Jan J. Melenhorst, David T. Teachey, Carl H. June, Stephan A. Grupp	15
3	Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL. 2016 ·Journal of Clinical Oncology ·David L. Porter, Norbert Frey, Jan J. Melenhorst, Wei‐Ting Hwang, Simon F. Lacey, Pamela A. Shaw, Anne Chew, Katherine T. Marcucci, Saar Gill, Alison W. Loren, Anthony R. Mato, Stephen J. Schuster, Lester Lledo, Holly McConville, Joan Gilmore, (unknown), Michael Kalos, Stephan A. Grupp, Bruce L. Levine, Carl H. June	28
4	Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial ovarian cancer. 2016 ·Journal of Clinical Oncology ·János L. Tanyi, Andrew R. Haas, Gregory L. Beatty, Caitlin Stashwick, Mark H. O’Hara, Mark A. Morgan, David L. Porter, Jan J. Melenhorst, Gabriela Plesa, Simon F. Lacey, Carl H. June	30
5	Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL). 2016 ·Journal of Clinical Oncology ·Noelle V. Frey, Pamela A. Shaw, Elizabeth O. Hexner, Saar Gill, Katherine T. Marcucci, Selina M. Luger, James K. Mangan, Stephan A. Grupp, Shannon L. Maude, Solveig G. Ericson, Bruce L. Levine, Simon F. Lacey, Jan J. Melenhorst, Carl H. June, David L. Porter	36
6	Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL 2015 ·Blood ·Susan R. Rheingold, (unknown), Shannon L. Maude, Richard Aplenc, (unknown), David M. Barrett, Colleen Callahan, (unknown), Irina Kulikovskaya, Simon F. Lacey, Bruce L. Levine, Jan J. Melenhorst, Pamela A. Shaw, (unknown), David T. Teachey, (unknown), Carl H. June, Stephan A. Grupp	35
7	Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer. 2015 ·Journal of Clinical Oncology ·Gregory L. Beatty, Mark H. O’Hara, Anne Marie Nelson, (unknown), Drew A. Torigian, Simon F. Lacey, Jan J. Melenhorst, Bruce L. Levine, Gabriela Plesa, Carl H. June	45
8	Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas 2015 ·Blood ·Stephen J. Schuster, Jakub Svoboda, Sunita D. Nasta, David Porter, Elise A. Chong, Daniel J. Landsburg, Anthony R. Mato, Simon F. Lacey, Jan J. Melenhorst, Anne Chew, Jens Hasskarl, Gaurav Shah, Mariusz A. Wasik, Katherine T. Marcucci, Zhaohui Zheng, Bruce L. Levine, Carl H. June	60
9	Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. 2015 ·Journal of Clinical Oncology ·Stephen J. Schuster, Jakub Svoboda, Sunita D. Nasta, David L. Porter, Anthony R. Mato, Gaurav Shah, Daniel J. Landsburg, Elise A. Chong, Simon F. Lacey, Jan J. Melenhorst, Anne Chew, Jens Hasskarl, Nirav N. Shah, Mariusz A. Wasik, Katherine T. Marcucci, Zhaohui Zheng, Bruce L. Levine, Carl H. June	32
10	Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells 2014 ·Blood ·Noelle V. Frey, Bruce L. Levine, Simon F. Lacey, Stephan A. Grupp, Shannon L. Maude, Stephen J. Schuster, Pamela A. Shaw, Wei‐Ting Hwang, Mariusz A. Wasik, Amrom E. Obstfeld, Mimi Leung, Angela Shen, Solveig G. Ericson, Jan J. Melenhorst, Carl H. June, David L. Porter	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact